SomaLogic licenses GNS Healthcare’s REFS™ technology for analysis of its SOMAscan®-derived proteomic data

Combining the world-leading proteomic and artificial intelligence/machine learning technologies to produce novel, actionable health insights across many diseases, conditions and markets

SomaLogic and GNS Healthcare announced today that SomaLogic has obtained a license to apply GNS Healthcare’s proprietary REFS™ (Reverse Engineering & Forward Simulation) causal machine learning technology to SomaLogic’s proprietary SOMAscan®-derived protein data sets. The goal of this agreement is to leverage REFS to rapidly accelerate the translation of SomaLogic’s massive protein data into meaningful and actionable information for individual and population health management.

Living organisms function through complicated interconnected biological networks that respond dynamically to factors such as diet, environment, medication, infection and disease. SomaLogic’s SOMAscan platform taps into these networks by repeatedly measuring the changing levels of thousands of proteins circulating through the body over time. These large data sets require increasingly powerful machine learning-based tools like GNS Healthcare’s unique REFS platform, which builds computational models of the biological networks from the raw data to reveal new understandings of disease and even potential interventions.

“Our ability to measure 5,000 proteins in each of hundreds of thousands of samples requires that we be able to analyze all those data in a way that will ultimately result in making a difference for individuals and their health providers,” said Alister Reynolds, CEO of SomaLogic. “We believe that GNS Healthcare’s powerful REFS technology has the potential to become a critical tool for extracting those meaningful health insights.”

“Our REFS platform has proven itself repeatedly with genomic, transcriptomic, metabolite, clinical, labs, EMR, claims, and other data types, and we are excited to see how well it performs on real-time biological measurements like proteins,” said Colin Hill, CEO and cofounder of GNS Healthcare. “SOMAscan-derived protein data are perfectly suited to the REFS workflow, and we look forward to our platform fully proving its value again in this setting.”

Further specifics about the agreement were not disclosed.

 

###

GNS Healthcare Contact
Patty Kellicker
VP, Marketing
T: 617-374-2384
pkellicker@gnshealthcare.com

SomaLogic Contact
Laura S. Mizoue, Ph.D.
Communications Specialist
T: 720-417-7509
lmizoue@somalogic.com

About GNS Healthcare
GNS Healthcare solves healthcare’s matching problem for leading health plans, biopharma companies, and health systems. We transform massive and diverse data streams to precisely match therapeutics, procedures, and care management interventions to individuals, improving health outcomes and saving billions of dollars. Our causal learning and simulation platform, REFS, accelerates the discovery of what works for whom and why. Learn more at www.gnshealthcare.com.

About SomaLogic
SomaLogic delivers meaningful and actionable health-management insights that empower individuals worldwide to continuously optimize their personal health and wellness throughout their lives. These essential insights, which are provided through a global network of partners and users, are derived from precise, proprietary, and personalized measurement of critical changes in an individual’s proteins over time. For more information, visit www.somalogic.com.

 

Translating the “Book of Life”

Measuring proteins reveals how genetic changes help give rise to complex traits and diseases

An article published today in the journal Nature brings us closer to understanding how differences in the genomes of individuals help contribute to common diseases and influence disease risk. Specifically, this study — by far the largest of its kind to date — revealed the effects of genetic variations on the levels of circulating blood proteins across thousands of individuals.

Proteins play essential roles throughout the body, and changes in their concentrations can reflect a person’s health status at any given time. Proteins are also the targets of most drugs, so the results of this study open the door to understanding individual responses to medical treatments, one of the goals of precision medicine.

Over the past decade, genome-wide association studies (GWAS) have identified of DNA variants that are linked to complex traits and diseases but have not explained exactly why they are important. The vast majority of DNA differences flagged by GWAS lie in regions of the genome with no known function and have small effect sizes. This makes establishing causal relationships or determining disease risk extremely difficult, even for conditions with a strong hereditary component such as obesity or cancer.

In the largest study of its kind to date, an international team led by researchers from the University of Cambridge and Merck tested 10.6 million DNA variants against the levels of 2,994 plasma proteins — measured using the SOMAscan® assay — in 3,301 healthy individuals of European heritage. They identified 1,927 genetic variants that impact the levels of 1,478 plasma proteins, of which ~90% had not been previously reported. Many of the variants act in “trans” (i.e., they lie far from the gene whose activity is altered, typically on different chromosomes). Trans associations are particularly interesting because they can highlight biological connections that are otherwise difficult to predict.

The authors cross-referenced their findings with known disease-associated GWAS variants to identify proteins that might cause disease. Some disease-associated proteins are targets of existing drugs, which suggests possible therapeutics for new indications. Connecting protein perturbations to disease endpoints also allows identification of new drug targets and potential safety concerns for drugs under development. These results also suggest that monitoring protein levels over time may suffice for regular health management.

Reference: Sun, BB et al. (2018) “Genomic atlas of the human plasma proteome” Nature 558: 73-79

See also the University of Cambridge news release.

 
 

Melody Harris, J.D., appointed Chief Legal Officer of SomaLogic

April 2, 2018 – Boulder, CO – SomaLogic announced today that Melody Harris has joined SomaLogic as the company’s Chief Legal Officer. Ms. Harris comes to SomaLogic from Qualcomm Life, a digital health subsidiary of Qualcomm, where she led the legal, global privacy, and Quality, Regulatory & Compliance groups as Vice President & Chief Counsel.

“I am delighted that Melody has chosen to take on this central role at SomaLogic at this critical time of company growth,” said Al Reynolds, Chief Executive Officer of SomaLogic. “She brings with
her a wealth of experience in healthcare technology and data-centric business models that we need to help us accelerate the delivery of SomaLogic’s breakthrough precision health insights into multiple markets around the world.”

SomaLogic was founded to transform healthcare by accurately measuring the changing state of an individual’s health over time, as revealed by changes in the proteins that make up the human body. Regularly monitoring thousands of proteins, unlike genome sequencing, can reveal not only real-time health status but also what interventions (e.g., diet, prescription and/or lifestyle changes) could maximize that status.

“SomaLogic is bringing together a unique technology and business plan to entirely change how people world-wide manage their personal health,” said Ms. Harris. “This rare opportunity to make a real difference in people’s lives is exciting, and I am eager to join the SomaLogic team to help make that vision a reality.”

Ms. Harris joined Qualcomm Life with the acquisition of HealthyCircles, where she served as General Counsel. At HealthyCircles, Ms. Harris built the company’s legal and compliance functions and advised on early-stage product development related to data and privacy by design. Prior to HealthyCircles, Ms. Harris held a variety of senior leadership roles, including President & General Counsel of an international IP management firm, Executive Vice President and General Counsel of an international software development and consulting firm, and Senior IP counsel to U S WEST/Qwest. She received her J.D., cum laude, from the Harvard Law School and her B.A., cum laude, in political science from the University of Denver.

###

SomaLogic Contact
Laura S. Mizoue, Ph.D.
Communications Specialist
T: 720-417-7509
lmizoue@somalogic.com

About SomaLogic
SomaLogic delivers health management insights in real-time that empower individuals to take action to improve their personal health and wellness. These essential insights, provided through a global network of partners and users, are derived from precise, proprietary, and personalized measurement of critical changes in an individual’s protein makeup throughout life. For more information, visit http://www.somalogic.com/.

 

SomaLogic launches new version of SOMAscan® assay

Expanded SOMAscan content measures approximately 5000 proteins simultaneously in a small blood sample

SomaLogic has launched a new version of their proprietary SOMAscan® assay. This new version measures approximately 5,000 unique human protein analytes, almost four times more than its predecessor. The optimized assay format also uses new robotic instrumentation, removing as many manual interventions as possible.

Unlike genes which remain largely the same throughout an individual’s lifetime, the proteins in the body are constantly changing in response to both internal and external factors, such as pathogens, diet, exercise and medications. The SOMAscan assay is the only technology capable of measuring thousands of proteins simultaneously, over a wide concentration range in a small sample of blood, which is critical for delivering personalized health information in real time.

The new version of the SOMAscan assay will be run in SomaLogic’s CLIA-certified laboratory, with a capacity of approximately 2,000 samples per week. On April 2, SomaLogic will start running samples from various studies on the new platform, to begin building precision health insights around metabolic and cardiovascular disease risk.

SomaLogic teams with Leeds Centre for Personalised Medicine and Health to deliver SOMAscan® platform in clinical healthcare

Personalized health insights derived from SomaLogic’s proprietary protein measurement technology will be tested in clinical healthcare settings in the UK

February 6, 2018 – Boulder, CO – SomaLogic announced today the establishment of a framework “Partnership for Personalized Health” with the Leeds Centre for Personalised Medicine and Health (CPMH), to be based in Leeds, UK. This collaboration – the first of its kind – aims to help individuals and professionals enhance health decisions by providing:

  • accurate assessment of the current state and future disease risks;
  • deeper understanding of causal and actionable factors that may drive these risks;
  • reliable monitoring of individuals to understand the effectiveness of interventions.

These activities will rely on personalized insights gained from SomaLogic’s unique ability to easily measure thousands of protein changes associated with a wide variety of diseases and conditions.

Leeds CPMH is a collaboration based at the University of Leeds involving general practitioners, the National Health Service, academics and the city council. By working closely with SomaLogic within this unique partnership, Leeds patients will also gain preferential access to additional health management insights provided exclusively through SomaLogic’s SOMAscan® protein-measurement platform.

“We are excited to be working with SomaLogic, a global leader in personalised medicine,” said Dr. Mike Messenger, head of the Leeds CPMH. “This partnership has the potential to deliver huge benefits for the people of Leeds, in terms of better health outcomes and more efficient use of health and care resources.”

Initially, the two organizations will develop a “test bed”multiple clinical areas, in both primary and secondary settings throughout the greater Leeds region. The Leeds CPMH and its strong network of healthcare providers and health leaders will provide the infrastructure and expertise to use insights derived from SomaLogic’s innovative technology to enhance clinical decision making and influence positive patient behavior change. Ultimately, the partners hope to dramatically lower the cost and increase the quality of personalized health screening and care delivery in Leeds and beyond.

“Leeds CPMH is at the forefront of integrating academia, industry, healthcare providers, and individual citizens to go beyond the ‘one size fits all’ approach to healthcare,” said Steve Williams, SomaLogic’s Chief Medical Officer. “We are thrilled that Leeds CPMH is the first of what we trust will be many test-bed partners around the world.”

For further details, please see the Leeds CPMH news article.

###

SomaLogic Contact
Laura S. Mizoue, Ph.D.
Communications Specialist
T: 720-417-7509
lmizoue@somalogic.com

About SomaLogic
SomaLogic delivers meaningful and actionable health-management insights that empower individuals worldwide to continuously optimize their personal health and wellness throughout their lives.

These essential insights, which are provided through a global network of partners and users, are derived from precise, proprietary, and personalized measurement of critical changes in an individual’s proteins over time. For more information, visit www.somalogic.com.

 

SomaLogic closes $200M financing round

Nan Fung Life Sciences and Madryn Asset Management join iCarbonX in investing to accelerate SomaLogic’s unique precision health insights delivery business

January 3, 2018 – Boulder, CO – SomaLogic announced today that it has capped its $200 million funding round, anchored by iCarbonX with substantial investments from Nan Fung Life Sciences and Madryn Asset Management. The successful round will accelerate SomaLogic’s goal of becoming the world’s leading provider of precision digital health insights.

SomaLogic uniquely and precisely measures thousands of human proteins rather than genes, and turns those measurements into insights that empower people to purposefully and meaningfully manage their individual health and wellness. SomaLogic’s “SOMAscan®” technology, which currently measures 5,000 proteins in a single sample, has successfully analyzed over 150,000 samples across more than 50 diseases or conditions, with plans for an additional 1 million more samples by the end of 2020. The continuously growing power of the SOMAscan technology, the massive proprietary data sets being accumulated and analyzed, and the strategy for turning those assets into a successful health insight company have together caught the attention of leading investors in emerging digital health markets.

“We are delighted to expand our relationship with SomaLogic and continue to support the company’s growth,” said Avinash Amin, Managing Partner at Madryn Asset Management. “We believe SomaLogic’s proteomics technology provides the basis for unique and differentiated insights into human health and disease, with broad implications for diagnosis and treatment.”

Understanding the changes over time in bodily proteins is being increasingly recognized by the medical community as essential to the effective personalized maintenance of health and management of disease. Unlike genes, proteins respond dynamically to changes in the body and the environment, offering meaningful and actionable health information in real-time.

“These new investments by Nan Fung and Madryn, two elite, global healthcare investors, are yet another huge vote of confidence in our strategic direction and the deep intrinsic value of our technology,” said Al Reynolds, SomaLogic’s CEO. “We are delighted that they recognize the huge potential of our technology to radically transform healthcare, and are joining us as valued partners to accelerate that goal.”

Specific financial details were not disclosed.

SomaLogic Contact
Laura S. Mizoue, Ph.D.
Communications Specialist
T: 720-417-7509
lmizoue@somalogic.com

About SomaLogic:
SomaLogic delivers meaningful and actionable health-management insights that empower individuals worldwide to continuously optimize their personal health and wellness throughout their lives.
These essential insights, provided through a global network of partners and users, are derived from precise, proprietary, and personalized measurement of critical changes in an individual’s proteins throughout life. For more information, visit http://www.somalogic.com/.

About Nan Fung Group:
Founded in 1954, Nan Fung Group is a conglomerate based in Hong Kong with global interests in real estate development and investment, financial investment, hotels and shipping. The Group continues to diversify its business and growth globally with interests in a diverse range of business partnerships, including life sciences.

About Nan Fung Life Sciences:
Nan Fung Life Sciences, part of Nan Fung Group, is a global life science investment platform with a significant presence in the US and Greater China.
Leveraging on the Group’s strong capital position, it has a long-term commitment to life sciences through direct investments and fund investments covering the full spectrum of the industry (including therapeutics, medical devices and diagnostics) and across different development stages.

About Madryn Asset Management, LP:
Madryn Asset Management, LP is a leading alternative asset management firm that invests in innovative healthcare companies specializing in unique and transformative products, technologies, and services. The firm draws on its extensive and diverse experience spanning the investment management and healthcare industries, and employs an independent research process based on original insights to target attractive economic opportunities that deliver strong risk-adjusted and absolute returns for its limited partners while creating long-term value in support of its portfolio companies. For additional information, please visit www.madrynlp.com.